Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of ACT-064992 in symptomatic pulmonary arterial hypertension
2007-002440-14Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Time to first morbidity or mortality event. Started Nov 2007; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2007-002440-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002440-14.